Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic

• Published in: European journal of pharmacology 2021-01, Vol.890, p.173643-173643, Article 173643
• Main Authors: Bhandari, Ranjana, Khanna, Garima, Kuhad, Anurag
• Format: Article
• Language: English
• Subjects: Animals; Antiviral Agents - therapeutic use; Convalescent plasma therapy and mesenchymal stem cell therapy; Coronavirus; COVID-19; COVID-19 - epidemiology; COVID-19 Drug Treatment; Drug repurposing; Full Length; Humans; Pandemics; SARS-CoV-2; SARS-COV2; Vaccines
• ISSN: 0014-2999; 1879-0712; 1879-0712
• DOI: 10.1016/j.ejphar.2020.173643

Coronaviruses are pleomorphic, enveloped, or spherical viruses, which have a size ranging from 80 to 120 nm. These viruses act on receptors that cause the triggering of fusion. Coronaviruses were first described after cultivation from patients with common colds by Tyrell and Bynoe in 1966. There are various subtypes of coronavirus, 7 out of these can cause infection in human beings. The Alpha subtype is responsible for mild infection showing symptoms or infection without any prevailing symptoms. On the other hand, the beta subtype is responsible for very serious diseases leading to fatality. The lineage of this novel SARS-CoV-2 falls under the beta lineage of the beta coronavirus which has been observed to have a relation to the MERS and SARS coronavirus. In the Huanan market selling seafood, the transition of this novel virus in humans from animals has occurred. It has the potential to be the cause of widespread fatality amongst the people of the globe. On August 16, 2020, the World Health Organisation had reported 2,1294,845 cases which are confirmed to date out of which 413,372 deaths have occurred. Currently, no targeted antiviral vaccines or drugs to fight against COVID-19 infection have been approved for use in humans. This pandemic is fast emerging and drug repurposing is the only ray of hope which can ensure quick availability. Vaccine development is progressing each day with various platforms such as DNA, Live Attenuated Virus, Non-Replicating Viral Vector, Protein Subunit, and RNA, being utilized for the development. COVID-19 attacks the immune system of the host & this can result in a cytokine storm. As a result, various herbal agents both acting as antivirals and immunomodulatory can also be used. Convalescent Plasma Therapy and Mesenchymal Stem Cell therapy are also being explored as a plausible therapeutic. There remains a considerable unmet need for therapeutics to be addressed. The development and availability of accessible and efficient therapy are essential for the treatment of patients. This review discusses the epidemiology, pathogenesis, the tale of origin, and transmission of COVID-19 or Sars-Cov2 virus and gives evidence of potential therapeutic agents that can be explored to cast away this pandemic. •World Health Organisation (WHO) declared COVID-19 or SARS-Cov2 as a global public health emergency on 30th January 2020.•COVID-19 is the third known zoonotic coronavirus disease after SARS and the Middle East respiratory syndrome (MERS)